Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exablate BBBD with Carboplatin in Recurrent Glioblastoma
NCT04417088Phase 2Completed
- Sponsor
- Insightec
- Start
- Nov 2020
- Primary completion
- Nov 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in glioblastoma (GBM), sponsored by Insightec. Primary endpoints: Adverse events at 12 months and Contrast intensity on MR imaging. Started Nov 2020; status: completed.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04417088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04417088.